Magazine : 
Bharat Biotech & Bilthoven Biologicals Collaborate for Oral Polio Vaccine Supply
Bharat Biotech has announced a strategic collaboration with Bilthoven Biologicals B.V., a subsidiary of the Serum Institute of India based in the Netherlands, to bolster the production and distribution of oral polio vaccines (OPVs). The partnership aims to enhance the supply security of OPVs both domestically in India and globally.
Under the agreement, Bharat Biotech will procure drug substances necessary for OPV production, sourced from Bilthoven Biologicals. This collaboration will facilitate the joint acquisition of regulatory approvals and licenses required for commercial manufacturing of OPVs in India. The drugs substances will be manufactured in the Netherlands and supplied to Bharat Biotech for production.
Krishna Ella, Executive Chairman of Bharat Biotech, emphasized the significance of this collaboration in ensuring a steady supply of OPVs and advancing India's mission to eradicate polio. Adar Poonawalla, CEO of Serum Institute of India, expressed their shared vision of global polio eradication and highlighted the importance of reducing the disease's impact on vulnerable populations.
This collaboration aligns with the global effort to achieve a polio-free world, particularly as the global polio eradication initiative enters a critical phase. Ella underscored the role of oral polio vaccines in India's Universal Immunisation Programme (UIP) and highlighted Bharat Biotech's extensive contribution as a major supplier to immunization programs worldwide.
Read More News :
Paradip Port Surpasses Kandla to Claim Title of India's Highest Cargo Handling Port
.jpg "PMP Institutes")